The TGA regulates AI-enabled software as a medical device under the Therapeutic Goods Act whenever its intended purpose is diagnosis, prevention, monitoring, prediction, prognosis or treatment. The framework is technology agnostic: intended purpose, not the presence of AI, triggers regulation, and regulated devices must be in the ARTG before supply. The guidance covers scope creep (an update adding clinical features can turn a non-device into a device), off-label use, evidence expectations for training data and limits on synthetic validation data. On 8 September 2026 the TGA amended the clinical decision support system exemption to clarify when it applies, effective 1 November 2026; the TGA says the scope of the exemption is unchanged, so developers should re-read their exemption reasoning against the amended wording before November.
Who this affects: Developers and suppliers of AI software with a clinical purpose, including LLM chatbots and clinical decision support.
